OPEN END TURBO OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 05:18:08 2024-06-26 EDT | ||
| 9.15 EUR / 9.65 EUR | +1.40% |
|
| Current month | -13.04% | ||
| 1 month | -12.79% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-25 | 9.27 | +3.92% |
| 24-06-24 | 8.92 | -6.40% |
| 24-06-21 | 9.53 | +0.63% |
| 24-06-20 | 9.47 | -3.27% |
| 24-06-19 | 9.79 | +0.72% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 03:48 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB9181 |
| ISIN | DE000JB91815 |
| Date issued | 2023-12-27 |
| Strike | 570.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 15.62 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.93 € |
|---|---|
| Lowest since issue | 7.89 € |
| Spread | 0.5 € |
| Spread % | 5.18% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
465.5
USD
Spread / Average Target
-1.75%
- Stock Market
- Certificates
- Certificat
